TWM604203U - Expandable microcapsule - Google Patents
Expandable microcapsule Download PDFInfo
- Publication number
- TWM604203U TWM604203U TW109212023U TW109212023U TWM604203U TW M604203 U TWM604203 U TW M604203U TW 109212023 U TW109212023 U TW 109212023U TW 109212023 U TW109212023 U TW 109212023U TW M604203 U TWM604203 U TW M604203U
- Authority
- TW
- Taiwan
- Prior art keywords
- weight
- gum
- parts
- lubricant
- sodium
- Prior art date
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
一種可膨脹微膠囊,具有一核心層,由300重量份的發泡劑、250重量份的高分子吸水材和60重量份的核心層潤滑劑組成,且發泡劑具有可與水反應而產生氣體之特性;以及一包覆層用以包覆於核心層之表面以構成一顆粒狀結構,該包覆層由重量比10%至40%的可食性吸水膠體、5%至40%的功能性健康食品添加物、2%至30%的乳化劑、4%至15%的包覆層潤滑劑及5%至40%的膜衣組成物所組成,且膜衣組成物具有抗胃酸分解而僅可在腸道中被分解之特性。An expandable microcapsule with a core layer consisting of 300 parts by weight of foaming agent, 250 parts by weight of polymer water-absorbing material and 60 parts by weight of core layer lubricant, and the foaming agent can react with water to produce The characteristics of gas; and a coating layer is used to coat the surface of the core layer to form a granular structure. The coating layer is composed of 10% to 40% by weight of edible water-absorbent colloid and 5% to 40% of function Sexual health food additives, 2% to 30% emulsifier, 4% to 15% coating lubricant and 5% to 40% film coating composition, and the film coating composition has resistance to gastric acid decomposition and It can only be broken down in the intestine.
Description
本創作係一種於食用後可在人體胃中物理性脹大,以增加飽足感的可膨脹微膠囊。This creation is an expandable microcapsule that can physically expand in the human stomach after eating to increase the feeling of fullness.
按,「肥胖」通常是指人體異常或過量脂肪累積,依據營養健康調查結果顯示:肥胖會加重身體機能負擔、罹患非傳染性疾病的重大風險因素、並且會導致許多慢性疾病的發生,例如,容易引起動脈硬化、心臟病、中風、心血管疾病、高血壓、高血脂症、糖尿病、惡性腫瘤、脂肪肝、代謝症候群等疾病。By the way, "obesity" usually refers to abnormal or excessive fat accumulation in the human body. According to the results of nutrition and health surveys, obesity can increase the burden of body functions, major risk factors for non-communicable diseases, and cause many chronic diseases. For example, It is easy to cause diseases such as arteriosclerosis, heart disease, stroke, cardiovascular disease, high blood pressure, hyperlipidemia, diabetes, malignant tumor, fatty liver, metabolic syndrome and so on.
而透過代謝刺激劑、食欲抑制劑、澱粉阻斷劑等藥物,雖可在短期內達到減重的功效,然而長期服用藥物也勢必會對人體造成許多不良的副作用,例如,目前合法的減肥藥品成份羅氏鮮 ®(Orlistat ®),是一種腸胃道胰臟脂肪分解酶的抑制劑,可用以使食物中的部份脂肪在腸胃道中無法被分解及吸收,藉此可減少來自食物當中一部份脂肪的熱量,以達到減肥的效果,但是羅氏鮮 ®有極大的副作用,包含干擾脂溶性維生素吸收、油便、胃脹氣、亦可能造成膽結石與肝腎損傷等,因此不適合長期使用;另有以芬他命(phentermine)-妥泰(topiramate)複方及氯卡色林(lorcaserin)作為主要成分的減肥藥品,其作用機轉都在於增加飽足感,以抑制食慾達到減重的目的,但會有頭暈、噁心或失眠、便祕等其他副作用,且這兩項減肥藥品對於心血管疾病產生的風險仍存有疑慮,並不適合有心血管疾病的患者服用。 Although drugs such as metabolic stimulants, appetite suppressants, and starch blockers can achieve weight loss in a short period of time, long-term use of drugs is bound to cause many adverse side effects to the human body. For example, the current legal weight loss drugs The ingredient Roche Fresh ® (Orlistat ® ) is an inhibitor of gastrointestinal pancreatic lipolytic enzymes, which can prevent part of the fat in food from being broken down and absorbed in the gastrointestinal tract, thereby reducing the amount of food from the food fat calories to achieve weight loss results, but Xenical ® have great side effects include interference absorption of fat-soluble vitamins, oils stools, bloating, may also cause gallstones and liver and kidney damage, and therefore not suitable for long-term use; and another to Phentermine (topiramate) compound and lorcaserin (lorcaserin) as the main ingredients of weight loss drugs, its mechanism of action is to increase satiety, to suppress appetite to achieve the purpose of weight loss, but will There are other side effects such as dizziness, nausea or insomnia, constipation, and these two weight-loss drugs still have doubts about the risk of cardiovascular diseases, and they are not suitable for patients with cardiovascular diseases.
有鑒於此,故如何解決上述問題,即為本創作所欲解決之首要課題。In view of this, how to solve the above-mentioned problems is the primary issue that this creation intends to solve.
本創作之主要目的,在於提供一種可膨脹微膠囊,其具有可於食用後在人體胃中物理性脹大之特點,並藉此即可增加飽足感而抑制食慾,以達到減肥目的,且不會對人體造成有任何藥物的不良副作用。The main purpose of this creation is to provide an expandable microcapsule, which has the characteristics of being physically swollen in the human stomach after consumption, and thereby can increase satiety and suppress appetite to achieve the purpose of weight loss, and Will not cause any adverse side effects of drugs to the human body.
為達前述之目的,本創作提供一種可膨脹微膠囊,包含有: 一核心層,由300重量份的發泡劑、250重量份的高分子吸水材和60重量份的核心層潤滑劑組成,且該發泡劑具有可與水反應而產生氣體之特性; 一包覆層,包覆於該核心層之表面以構成一顆粒狀結構,該包覆層由重量比10%至40%的可食性吸水膠體、5%至40%的功能性健康食品添加物、2%至30%的乳化劑、4%至15%的包覆層潤滑劑及5%至40%的膜衣組成物所組成,且該膜衣組成物具有抗胃酸分解而僅可在腸道中被分解之特性。 In order to achieve the aforementioned purpose, this creation provides an expandable microcapsule, which contains: A core layer consisting of 300 parts by weight of foaming agent, 250 parts by weight of polymer water-absorbing material and 60 parts by weight of core layer lubricant, and the foaming agent has the characteristic of reacting with water to generate gas; A coating layer, covering the surface of the core layer to form a granular structure, the coating layer is composed of 10% to 40% by weight of edible water-absorbing colloid, 5% to 40% of functional health food additives , 2% to 30% emulsifier, 4% to 15% coating lubricant and 5% to 40% film coating composition, and the film coating composition has resistance to gastric acid decomposition and can only be in the intestine The decomposed characteristics of the Tao.
較佳地,食用者除了可直接食用預定量的可膨脹微膠囊,使其可在人體胃中物理性脹大以增加飽足感而抑制食慾,還可依需求將其製成錠狀,或亦可先將預定量的可膨脹微膠囊裝填在由二外型對稱之半囊體所對接組成的中空囊體中,以方便食用者服用。Preferably, in addition to directly consuming a predetermined amount of expandable microcapsules, the eater can physically expand in the human stomach to increase satiety and suppress appetite, and can also be made into tablets according to needs, or It is also possible to fill a predetermined amount of expandable microcapsules in a hollow capsule composed of two symmetrical half-capsules, so as to facilitate the consumption of the eater.
而本創作之上述目的與優點,不難從下述所選用實施例之詳細說明與附圖中獲得深入了解。It is not difficult to gain an in-depth understanding of the above-mentioned objectives and advantages of this creation from the detailed description and drawings of the selected embodiments below.
首先,請參閱第1、2圖所示,為本創作所提供一種可膨脹微膠囊10,其主要由一核心層11及一包覆於該核心層11表面之包覆層21所構成,其中:First, please refer to Figures 1 and 2. An
該核心層11,由300重量份的發泡劑、250重量份的高分子吸水材和60重量份的核心層潤滑劑組成,且該發泡劑具有可與水反應而產生氣體之特性。The
該包覆層21,用以相對包覆於該核心層11之表面以構成一顆粒狀結構,該包覆層21由重量比10%至40%的可食性吸水膠體、5%至40%的功能性健康食品添加物、2%至30%的乳化劑、4%至15%的包覆層潤滑劑及5%至40%的膜衣組成物所組成,且該膜衣組成物具有抗胃酸分解而僅可在腸道中被分解之特性。The
而在實際製作上,本創作的發泡劑係由100至300重量份的酸性化合物和130至410重量份的鹼性化合物組成,且所述發泡劑在使用前以40°C至80°C條件下乾燥2至4小時,過40至100目篩。所述酸性化合物和鹼性化合物優選為:酸性化合物200重量份、鹼性化合物270重量份;或酸性化合物240重量份、鹼性化合物400重量份;或酸性化合物160重量份、鹼性化合物140重量份。In actual production, the foaming agent of this creation is composed of 100 to 300 parts by weight of acidic compounds and 130 to 410 parts by weight of basic compounds, and the foaming agent is heated at 40°C to 80°C before use. Dry under C conditions for 2 to 4 hours, and pass through a 40 to 100 mesh sieve. The acidic compound and the basic compound are preferably: 200 parts by weight of acidic compounds and 270 parts by weight of basic compounds; or 240 parts by weight of acidic compounds and 400 parts by weight of basic compounds; or 160 parts by weight of acidic compounds and 140 parts by weight of basic compounds. Copies.
較佳地,上述的酸性化合物,可以是檸檬酸、酒石酸、富馬酸、己二酸、蘋果酸、抗壞血酸、水溶性氨基酸(例如精氨酸)稀鹽酸、硼酸、酒石酸氫鈉、酒石酸氫鉀、檸檬酸氫鈉、檸檬酸氫鉀、磷酸二氫鉀、磷酸二氫鈉的其中一種或其任意組合。且舉凡是可食用的有機酸、無機酸及其等溶於水後呈酸性的鹽類,均可以作為酸性化合物使用。在酸性化合物中以檸檬酸和/或酒石酸為佳。Preferably, the above-mentioned acidic compound can be citric acid, tartaric acid, fumaric acid, adipic acid, malic acid, ascorbic acid, water-soluble amino acids (such as arginine), dilute hydrochloric acid, boric acid, sodium hydrogen tartrate, potassium hydrogen tartrate , Sodium hydrogen citrate, potassium hydrogen citrate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, or any combination thereof. In addition, all edible organic acids, inorganic acids, and salts that are acidic after being dissolved in water can be used as acidic compounds. Among the acidic compounds, citric acid and/or tartaric acid are preferred.
較佳地,上述的鹼性化合物,可以是碳酸鈉、碳酸氫鈉、碳酸鉀、碳酸氫鉀、碳酸鈣、甘氨酸碳酸鈉、甘氨酸碳酸鉀的其中一種或其任意組合。且舉凡是可食用的鹼金屬或鹼土金屬的碳酸鹽、過碳酸鹽和碳酸氫鹽以及它們的混合碳酸鹽均可以作為能產生二氧化碳氣體的鹼性化合物,在鹼性化合物中以碳酸鈉、碳酸氫鈉、碳酸鉀、碳酸氫鉀至少其中的一種為佳。另外,在考量一天服用多次含鈉發泡劑,會使不宜多吃鈉的食用者帶來不良後果的情況下,則可考慮少用碳酸鈉、碳酸氫鈉,而改用碳酸氫鉀、碳酸鉀、碳酸鈣、碳酸鋅等不含鈉或含鈉低的二氧化碳源代替。Preferably, the above-mentioned basic compound may be one or any combination of sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, calcium carbonate, sodium glycine carbonate, and potassium glycine carbonate. In addition, all edible alkali metal or alkaline earth metal carbonates, percarbonates, bicarbonates and their mixed carbonates can be used as basic compounds that can generate carbon dioxide gas. Among the basic compounds, sodium carbonate and carbonic acid At least one of sodium hydrogen, potassium carbonate, and potassium hydrogen carbonate is preferred. In addition, considering that taking sodium-containing foaming agents multiple times a day will cause adverse consequences for consumers who are not suitable to eat more sodium, consider using less sodium carbonate and sodium bicarbonate instead of potassium bicarbonate, Potassium carbonate, calcium carbonate, zinc carbonate and other non-sodium or low-sodium carbon dioxide sources are substituted.
較佳地,本創作的高分子吸水材為聚丙烯酸鈉,且所述高分子吸水材經超微粉碎達300目以上,在40°C至80°C條件下乾燥2至5小時。Preferably, the polymer water-absorbing material of the present invention is sodium polyacrylate, and the polymer water-absorbing material is superfinely pulverized to reach 300 meshes or more, and dried at 40°C to 80°C for 2 to 5 hours.
而本創作的核心層潤滑劑主要由20至60重量份的內加潤滑劑和2至6重量份的外加潤滑劑所組成。較佳地,所述內加潤滑劑為聚乙二醇4000或聚乙二醇6000,外加潤滑劑則為硬脂酸鎂、滑石粉或亮氨酸L型或亮氨酸DL型的其中一種或其任意組合,而所述的內加潤滑劑和外加潤滑劑優選為:內加潤滑劑40重量份和外加潤滑劑4重量份,或內加潤滑劑25重量份和外加潤滑劑5重量份,或內加潤滑劑57重量份和外加潤滑劑3重量份。The core layer lubricant of this creation is mainly composed of 20 to 60 parts by weight of internal lubricant and 2 to 6 parts by weight of external lubricant. Preferably, the internal lubricant is polyethylene glycol 4000 or polyethylene glycol 6000, and the external lubricant is magnesium stearate, talc, or leucine L type or leucine DL type. Or any combination thereof, and the internal lubricant and external lubricant are preferably: 40 parts by weight of internal lubricant and 4 parts by weight of external lubricant, or 25 parts by weight of internal lubricant and 5 parts by weight of external lubricant , Or 57 parts by weight of internal lubricant and 3 parts by weight of external lubricant.
本創作核心層11的製備方法為:依上述配方比例將發泡劑、高分子吸水材、內加潤滑劑混合,過篩(依產品需求),混勻,加240重量份的無水乙醇製軟材,經過篩(依產品需求)制粒後,在40°C至80°C條件下乾燥,使混合物顆粒含水率達到3%以下,接著過篩整理(依產品需求),再添入外加潤滑劑混勻後,即可製得本創作呈顆粒狀之核心層11。The preparation method of the
接著,就本創作之包覆層21各組成物說明如下,其中:Next, the composition of the
該包覆層21主要由重量比10%至40%的可食性吸水膠體、5%至40%的功能性健康食品添加物、2%至30%的乳化劑、4%至15%的包覆層潤滑劑及5%至40%的膜衣組成物所組成。包覆層21中之可食性吸水膠體包括天然產生的材料,例如植物分泌物、種子膠和海藻提取物,或者亦可以是化學改性的材料,例如改性的纖維素、澱粉或天然橡膠衍生物。在可行的實施方案中,可食性吸水膠體可由果膠、蒟蒻粉、阿拉伯膠、卡拉膠、海藻酸鹽、洋菜、關華豆膠、黃原膠、刺槐豆膠、明膠、結蘭膠(gellangum)、半乳甘露聚糖、黃蓍膠、刺梧桐樹膠、可得然膠(curdlan)、殼聚糖、木葡聚糖、β-葡聚糖、帚叉藻膠(furcellaran)、達瓦樹膠(Ghattigum)、圍涎樹膠(tamarin)、細菌膠、海藻酸丙二醇酯、羧甲基洋槐豆膠、低甲氧基果膠、乳化鈣與果膠混合物、改性的微晶纖維素、改性的羧甲基纖維素(CMC)、改性的甲基纖維素(MC)、改性的羥丙基甲基纖維素(HPCM)以及改性的羥丙基纖維素(MPC)的其中一種或其任意組合。The
而包覆層21中之功能性健康食品添加物包括但不限於對人體有益的纖維素、益生菌或維生素,以及所有可幫助消化、提高新陳代謝、促進脂肪燃燒、幫助排便順暢、抑制醣類及油脂吸收等對人體有益的添加物。The functional health food additives in the
而包覆層21中之膜衣組成物,經設計可在胃的酸性環境中保持完整不被消化並可吸收胃裡面的水份,但可在腸之較鹼性環境中溶解,此膜衣組成物包含成膜劑、抗黏劑及溶劑。其中,成膜劑可包含但不限於蟲膠甲基纖維素、乙基纖維素、丙基甲基纖維素、羥丙基甲基纖維素鄰苯二甲酸酯(Hydroxypropyl Methyl Cellulose Phthalate;HPMCP)、果膠、海藻膠、海藻酸鈉、羥丙基纖維素、羥丙基甲基纖維素、羥乙基纖維素、聚乙烯吡咯啶酮、聚乙二醇、甲基丙烯酸胺基烷酯共聚物、麥芽糊精及聚葡萄糖的其中一種或其任意組合。優選的,具有胃不溶性的成膜劑為海藻酸鈉。另基於膜衣組成物之使用量為100重量百分比,此膜衣組成物包含1%至25%之成膜劑、0.5%至15%之抗黏劑,以及60%至95%之溶劑。The film coating composition in the
此外,可進一步在包覆層21中添加乳化劑,可食性吸水膠體與乳化劑的質量比可為7:1,所述乳化劑可特別選自卵磷脂、甘油的脂肪酯、蔗糖或山梨糖醇,以可因應存在高含量的蛋白質或油脂之使用環境。且進一步地,根據生產需要加入便於制粒的包覆層潤滑劑,所述包覆層潤滑劑為聚乙二醇4000、聚乙二醇6000、十二烷基硫酸鈉、十二烷基硫酸鎂、L-亮氨酸、苯甲酸鈉、油酸鈉、氯化鈉、醋酸鈉、硼酸、硬脂酸鎂、滑石粉、微粉矽膠、蔗糖脂肪酸酯和硬脂醯富馬酸鈉、亮氨酸L型或亮氨酸DL型中的一種或其任意組合。In addition, an emulsifier can be further added to the
較佳地,本創作包覆層21用以包覆於核心層表面的方法,可藉由習用藥理學技術以製成顆粒狀結構。習用藥理學技術包括例如以下方法中之一者或其組合:(1)乾式混合,(2)直接壓縮,(3)研磨,(4)乾式或非水粒化,(5)濕式粒化,(6)熔融,或(7)擠出/滾圓;其他方法例如常用的溶劑蒸發法(如:噴霧乾燥法、分層或流化床造粒法、旋轉盤、三相乳化技術等),適合利用溶劑蒸發法的較佳溶劑包括醇類(例如:甲醇、乙醇、正丙醇、異丙醇及丁醇)、酮類(例如:丙酮、甲基乙基酮及甲基異丁基酮)、酯類(例如:乙酸乙酯及乙酸丙酯)及各種不同其他溶劑,如:異丙醚、乙腈、二氯甲烷、氯仿、己烷、甲苯、四氫呋喃、環狀醚類,及1,1,1-三氯乙烷;亦可使用低揮發性溶劑,如:二甲基乙醯胺或二甲亞碸。亦可使用溶劑之混合物,如:20%乙醇與80%丙酮及其與水之混合物。Preferably, the method for covering the surface of the core layer with the
以上述各組成物所製成之本創作可膨脹微膠囊10,透過在其核心層11中加入高分子吸水材,可及時除去不可避免的酸鹼反應所產生的水,使核心層中發泡劑的顆粒表面可得到隔離,並保持乾燥的狀態,阻止酸鹼反應,從而解決發泡劑存在易吸潮脹氣不穩定的問題,且在實際作用下,更可確保發泡劑吸水後發泡速度快之功效,另一方面透過高分子吸水材吸水後,可以幫助穩定包覆層的膠體形狀,而具有優良的成型效果。The
本創作之可膨脹微膠囊10經食用而進入人體胃中時,藉由包覆層21的可食性吸水膠體吸收水份後會軟化,且其核心層11也會因吸收水份脹大,同時因核心層11中的發泡劑與水反應產生二氧化碳,使包覆於核心層11外的包覆層21可受發泡劑持續產生的二氧化碳鼓吹而快速膨脹變大(如第2圖所示),如此一來,即可達到物理性脹大的效果,並藉此即可大幅增加食用者的飽足感,以進而抑制食慾;另一方面,透過包覆層21中具特定組成之膜衣組成物不會胃酸環境分解崩壞,因此可在胃中保持其膨脹型體,但當其進入腸道較鹼性環境中即會開始崩散,故,當食用者食用本創作可膨脹微膠囊10時,包覆層21中所含有的功能性健康食品添加物可延遲至腸道中始釋放出,而不會被胃酸所分解破壞,進而可提高被人體所吸收之濃度,以提升其功效。透過本創作所提供的可膨脹微膠囊具有可在人體胃中物理性脹大之特點,並藉此即可增加飽足感而抑制食慾,以達到減肥目的,且其不含有任何藥物成分,更可確保不會對人體造成任何不良副作用。When the
此外,本創作所提供之可膨脹微膠囊在實際應用上,食用者除了可直接食用預定數量的可膨脹微膠囊10,使其可在人體胃中物理性脹大以增加飽足感而抑制食慾,還可依需求將預定數量的可膨脹微膠囊10以前述習用藥理學技術,透過添加適當的黏合劑與有機溶劑製成如第3圖所示之錠狀,以方便食用者服用,其中黏合劑用以賦予將多個可膨脹微膠囊10相互黏結之作用,其包括例如海藻酸及其鹽;纖維素衍生物,例如羧甲基纖維素、甲基纖維素、羥丙基甲基纖維素、羥乙基纖維素、羥丙基纖維素、乙基纖維素(例如,微晶纖維素;微晶右旋糖;直鏈澱粉;矽酸鎂鋁;多糖酸;膨潤土;明膠;聚乙烯基吡咯啶酮/乙酸乙烯酯共聚物;交聯聚維酮;聚維酮;澱粉;預膠凝澱粉;黃蓍膠;糊精;糖,例如,蔗糖、葡萄糖、右旋糖、糖蜜、甘露醇、山梨醇、木糖醇及乳糖;天然或合成樹膠,例如阿拉伯樹膠(acacia)、黃蓍膠、甘地膠(ghatti gum) 聚維酮(povidone)、伊莎貝果殼黏液;聚乙烯基吡咯啶酮、聚甲基丙烯酸酯、松木多糖、聚乙二醇、丙二醇、聚氧化乙烯、蠟、海藻酸鈉亦包括(例如)、洋菜、褐藻酸、卡波姆、卡拉膠、瓜爾豆膠、鄰苯二甲酸乙酸纖維素、硬脂酸、長角豆(ceratonia)、聚維酮(povidone)中的一種或其任意組合。而所述有機溶劑則可選自乙醇、異丙醇、四氫呋喃、異丙醚、丙酮、甲乙酮、二氯甲烷或這些溶劑的混合物。In addition, in the practical application of the expandable microcapsules provided by this creation, users can directly consume a predetermined number of
另如第4圖所示的本創作另一實施態樣,亦可先將預定數量的可膨脹微膠囊10裝填在由二外型對稱之半囊體31、32所對接組成的中空囊體3中,以方便食用者服用,該中空囊體3之成份係包含可由人體吸收之明膠或植物性成份,如甲基纖維素、羥丙基纖維素、丙基甲基纖維素等。In addition, as shown in Fig. 4 in another embodiment of the present creation, a predetermined number of
惟,以上實施例之揭示僅用以說明本創作,並非用以限制本創作,故舉凡數值之變更或等效元件之置換仍應隸屬本創作之範疇。However, the disclosure of the above embodiments is only used to illustrate the creation, not to limit the creation, so any changes in values or replacement of equivalent components should still belong to the scope of the creation.
綜上所述,當可使熟知本項技藝者明瞭本創作確可達成前述目的,實已符合專利法之規定,故依法提出申請。To sum up, when people who are familiar with this art know that this creation can indeed achieve the aforementioned purpose, and that it has actually complied with the provisions of the Patent Law, they should file an application in accordance with the law.
10:可膨脹微膠囊 11:核心層 21:包覆層 31、32:半囊體 30:中空囊體10: Expandable microcapsules 11: core layer 21: Cladding 31, 32: half cyst 30: Hollow capsule
第1圖為本創作可膨脹微膠囊之組成結構示意圖。 第2圖為本創作可膨脹微膠囊之物理性脹大示意圖。 第3圖為本創作製成錠狀之組成結構示意圖。 第4圖為本創作另一實施態樣之組成結構示意圖。 Figure 1 is a schematic diagram of the composition structure of the created expandable microcapsule. Figure 2 is a schematic diagram of the physical expansion of the created expandable microcapsules. Figure 3 is a schematic diagram of the composition structure of the creation made into ingots. Figure 4 is a schematic diagram of the composition structure of another implementation aspect of the creation.
10:可膨脹微膠囊 10: Expandable microcapsules
11:核心層 11: core layer
21:包覆層 21: Cladding
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW109212023U TWM604203U (en) | 2020-09-14 | 2020-09-14 | Expandable microcapsule |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW109212023U TWM604203U (en) | 2020-09-14 | 2020-09-14 | Expandable microcapsule |
Publications (1)
Publication Number | Publication Date |
---|---|
TWM604203U true TWM604203U (en) | 2020-11-21 |
Family
ID=74202885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109212023U TWM604203U (en) | 2020-09-14 | 2020-09-14 | Expandable microcapsule |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWM604203U (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI763036B (en) * | 2020-09-14 | 2022-05-01 | 王子賓 | expandable microcapsules |
WO2022141308A1 (en) * | 2020-12-30 | 2022-07-07 | 苏州大学 | Edible capsule, preparation method therefor and use thereof |
-
2020
- 2020-09-14 TW TW109212023U patent/TWM604203U/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI763036B (en) * | 2020-09-14 | 2022-05-01 | 王子賓 | expandable microcapsules |
WO2022141308A1 (en) * | 2020-12-30 | 2022-07-07 | 苏州大学 | Edible capsule, preparation method therefor and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI763036B (en) | expandable microcapsules | |
TWM604203U (en) | Expandable microcapsule | |
US5262172A (en) | Compositions of gastric acid-resistant microspheres containing buffered bile acids | |
US5096714A (en) | Prolonged release drug tablet formulations | |
AU774957B2 (en) | Hydrodynamically balancing oral drug delivery system | |
US20050222082A1 (en) | Agent for producing a sensation of safety and for weight loss | |
JPS62195323A (en) | Gastric resident particle | |
EP1509208A1 (en) | Hydrodynamically balancing oral drug delivery system with biphasic release | |
WO2008100107A1 (en) | Controlled-release preparation containing cilostazol and process for the preparation thereof | |
EP1615632B1 (en) | Floating oral formulations for controlled release of betaine | |
JPH0568446B2 (en) | ||
KR19990079034A (en) | Sephacller-containing sustained-release tablets and preparation method thereof | |
CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
JP2005261376A (en) | Chitosan-containing assistant food | |
WO2019115501A1 (en) | Oral gastroretentive sustained-release pharmaceutical formulation | |
CN101836984A (en) | Dextral-rabeprazole-magnesium-containing pharmaceutical preparation and preparation method thereof | |
CN103520136A (en) | Montelukast sodium pulse capsule and preparation method thereof | |
JP5452056B2 (en) | Oral medicine | |
CN101002736A (en) | Slow-release preparation containing polyheteroside of tripterygium wilfordii | |
CN1195525A (en) | Melatonin slow-releasing agent and its production process | |
AU2021102577A4 (en) | Biopolymer nanosphere containing nicotinamide mononucleotide, preparation method therefor and use thereof | |
CN1903176B (en) | Dry suspensoid of Repirinast and its prepn. method | |
CN103040761A (en) | Novel metformin hydrochloride sustained release pellets and preparation method thereof | |
TWM632573U (en) | Oral particle containing weight loss active ingredient | |
EP3891188A1 (en) | Composition that is self-foaming in an acid medium and method for preparing same |